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ABSTRACT 
Objective:- To determine fetomaternal outcome of pregnancy in women with mild-moderate mitral stenosis. 
Material and methods:- This study was carried out in the Labour Ward Department of Obstetrics & 
Gynaecology, Nishtar Hospital Multan from January 2016 to  December 2016. One hundred and thirty five cases 
of mitral stenosis fulfilling the inclusion criteria were recruited from outdoor and labor ward of obstetric and 
gynecology department Nishtar Hospital Multan. Results:- Mean age of patients was 29.09±4.43 years. Majority 
of the patients 88(65.2%) women were between 26 to 30 years of age and there were 58(43.0%) primipara. 
Regarding fetomaternal outcome, congestive heart failure was observed in 43 patients (31.9%), preterm 
deliveries in 23 (17.0%) and intrauterine growth restriction in 30(22.2%) cases. Conclusion:- Among the 
complications, congestive heart failure had a high frequency of 31.9% followed by intrauterine growth 
restriction 22.2% and preterm deliveries 17.0%.  
Key Words:- Valvular heart disease, mitral stenosis, congestive heart failure.  
 
INTRODUCTION 
Heart diseases are the most important non obstetrical causes of maternal death during pregnancy. Maternal heart 
diseases comprise 0.2% to 3% of all pregnancies1 and are responsible for 10% to 25% of maternal deaths.2 
Women with valvular heart disease had a high rate of clinical deterioration and a marked increase in morbid 
events during pregnancy, including congestive heart failure (CHF), arrhythmias and need to either initiate or 
increase cardiovascular drug therapy or to hospitalize patients during pregnancy. Although rheumatic heart 
disease is decreasing worldwide, it is still an important cause of valvular problems.3 In developing countries like 
Pakistan4,5 rheumatic heart disease is very common whereas mitral stenosis (MS) is the most common valvular 
lesion (90%).
6
 Profound hemodynamic alterations occur during pregnancy, labour and in the postpartum period.
7
 
These changes begin during the first five to eight weeks of pregnancy and reach their peak late in the second 
trimester.8 Blood volume increases by 40-50%,9 cardiac output by 30-50%,10 heart rate by 10-15 beat/minute11 in 
addition to rise in stroke volume and decline vascular peripheral resistant.
12,13
 These changes return to pre-
pregnancy baseline within 3-4 weeks following delivery.
14
 Pregnancy has a deleterious effect on stenotic 
lesions.
15 
 
Problems associated with mitral stenosis in pregnancy are due to further narrowing of mitral valve and the 
haemodynamic change that take place.
16
 Increase in intravascular volume can lead to an increase in transmitral 
gradient and left atrial pressure and also cause pulmonary oedema.
17
 Maternal mortality for patients with MS is 
significantly higher (6.8%) for those who are New York Heart Association (NYHA) class 3 and 4 than patients 
who are NYHA class 1 and 2 (0.4%), particularly during labour and delivery.18 Majority of pregnant women 
with mitral stenosis are diagnosed during pregnancy. Formerly asymptomatic patients become symptomatic due 
to hemodynamic changes associated with pregnancy and the development of symptoms is the reason for their 
first cardiac evaluation.19 The presenting symptoms of mitral stenosis are dyspnea on exertion, orthopnea and 
paroxysmal nocturnal dyspnea. Physical examination of patient with mitral stenosis show pulse pressure which 
may be reduced, mitral facies with plethoric cheeks, raised JVP, basal crepts, S1 loud and mid diastolic murmur 
at mitral area with no radiation. Diagnosis is confirmed by ECG (P mitral and low voltage), and echocardiograph 
(mitral valve area less than 4 cm2). Predictors of adverse maternal outcome include;  Severity of mitral stenosis 
(valve < 1.5 cm
2
). And Functional class of heart disease as determined by level of activity that lead to dyspnea 
(New York Heart Association Class III & IV).
14
    Fetal outcome depends on the degree of maternal well being. 
Fetal mortality is not exceptionally high in patients with NYHA class I and II, however if there is associated 
pulmonary hypertension there is a risk of abortions, intrauterine growth restriction (IUGR), preterm delivery and 
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early neonatal death.
20
 
 
In one study, the risk of maternal complications during pregnancy raised from 26% in mild mitral stenosis 
(defined as mitral valve area > 1.5 cm
2
) to 38% in moderate mitral stenosis (mitral valve area 1.1–1.5 cm
2
) and 
up to 67% in severe mitral stenosis (mitral valve area < 1.0 cm
2
).
21
 So if mitral stenosis is diagnosed early and 
managed properly with multidisciplinary approach, involving trained obstetrician, cardiologist, anesthetist, 
pediatrician and nurse, it result in successful fetomaternal outcome in majority of cases.22 In one study, 
frequency of mild and moderate mitral stenosis was 41% and 39% respectively. In this study maternal outcome 
in terms of congestive heart failure in mild and moderate mitral stenosis was 11% and 61% respectively. Fetal 
outcome in terms of preterm delivery and IUGR in mild and moderate mitral stenosis was 5% & 28% and 16% 
and 27% respectively.23 
 
This study was planned to determine magnitude of fetomaternal outcome during pregnancy with mild to 
moderate mitral stenosis so that guideline could be made to handle these cases efficiently. 
 
MATERIAL AND METHODS 
This study was carried out in the Labour Ward Department of Obstetrics & Gynaecology, Nishtar Hospital 
Multan from January 2016 to  December 2016. One hundred and thirty five cases of mitral stenosis fulfilling the 
inclusion criteria were recruited from outdoor and labor ward of obstetric and gynecology department Nishtar 
Hospital Multan. 
 
RESULTS 
There were 23(17.0%) preterm deliveries, and 112 (83.0%) term deliveries. Regarding maternal outcome, 
congestive heart failure was observed in 43 patients (31.9%) and fetal outcome showed preterm deliveries in 23 
(17.0%) and intrauterine growth restriction 30(22.2%) cases. In present study, there were 135 patients with mild 
to moderate mitral stenosis evaluated for fetomaternal outcome.  Mean gestational age was 37.04±2.74 weeks. 
Mean age of mothers was 29.09±4.43 years (Table No. 9) and age range was 18–40 years. There were 10(7.4%) 
women of the age of ≤ 20 years, 9(6.7%) women between 21 to 25 years, 88(65.2%) women between 26 to 30 
years, 15(11.1%) women between 31 to 35 years, and 13(9.6%) women between 36 to 40 years as shown in 
Table-1. There were 39(28.9%) primigravidae, 13(9.6%) nullipara, 58(43.0%) primipara and 25(18.5%) women 
of para 2–4 (Table-2). Out of the total 10 patients ≤ 20 years, 1(10%) had congestive heart failure, 2(20%) had 
preterm delivery and 3(30%) had intrauterine growth restriction. Out of the total 9 patients between 21–25 years, 
6(66.7%) had congestive heart failure, 4(44.4%) had preterm delivery and 0(0%) had intrauterine growth 
restriction. Out of the total 88 patients between 26–30 years, 28(31.8%) congestive heart failure, 11(12.5%) had 
preterm delivery and 20(22.7%) had intrauterine growth restriction. Out of the total 15 patients between 31–35 
years, 5(33.3%) had congestive heart failure, 5(33.3%) had preterm delivery and 4(26.7%) had intrauterine 
growth restriction. Out of the total 13 patients between 36–40 years, 3(23.1%) had congestive heart failure, 
1(7.7%) had preterm delivery and 3(23.1%) had intrauterine growth restriction as shown in Table No. 10. Age 
had no significant effect on occurrence of CHF between age groups (p=0.64). Preterm delivery was significantly 
high in age group 26–30 years (p=0.036). There was no significant difference among age groups regarding 
IUGR (p=0.165).   
 
Out of the total 39 primigravida, 12(30.8%) had congestive heart failure, 7(17.9%) had preterm delivery and 
8(20.5%) had intrauterine growth restriction. Out of the total 13 nullipara, 4(30.8%) had congestive heart failure, 
3(23.1%) had preterm delivery and 1(7.7%) had intrauterine growth restriction. Out of the total 58 primipara, 
15(25.9%) congestive heart failure, 11(18.9%) had preterm delivery and 12(20.7%) had intrauterine growth 
restriction. Out of the total 25 Para 2–4, 12(48%) had congestive heart failure, 2(8%) had preterm delivery and 
9(36%) had intrauterine growth restriction (Table No. 11). 
 
Parity had no significant effect on the occurrence of CHF (p=0.172), preterm delivery (p=0.432) and IUGR 
(p=0.288). Out of the total 23 pregnancies < 37 weeks gestation, 1(4.4%) had congestive heart failure, 23(100%) 
had preterm delivery and 1(4.4%) had intrauterine growth restriction. Out of the total 112 term pregnancies, 
42(37.5%) had congestive heart failure, 0(0%) had preterm delivery and 29(25.9%) had intrauterine growth 
restriction (Table No. 12). Gestational age had no significant effect on the occurrence of CHF (p=0.255) and 
IUGR (p=0.534). Preterm deliveries were significantly more (p<0.0001) in gestational age < 37 weeks. 
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Table-1 
Age Distribution (n=135) 
Age (years) No. of Patients Percentage 
< 20 10 07.4 
21 –– 25 09 06.7 
26 – 30 88 65.2 
31 – 35 15 11.1 
36 – 40 13 09.6 
 
Table-2 
Parity Distribution (n=135) 
Parity No. of Patients Percentage 
Primigravida 39 28.9 
Nullipara 13 09.6 
Primipara 58 43.0 
Para 2–4 25 18.5 
 
TABLE-3 
Age Distribution of the Patients in Relation to Outcome  
Age            (in 
years) 
Total No. of 
Patients  
Outcome (Maternal & Fetal) 
Congestive heart 
failure 
p
-v
a
lu
e
  
Preterm 
delivery 
p
-v
a
lu
e
  
Intrauterine 
growth restriction 
p
-v
a
lu
e
  
≤ 20 10 1(10%) 
p
=
0
.0
6
4
 
 
2(20%) 
p
=
0
.0
3
6
 
 
3(30%) 
p
=
0
.1
6
5
 
 
21 – 25 9 6(66.7%) 4(44.4%) 0(0%) 
26 – 30 88 28(31.8%) 11(12.5%) 20(22.7%) 
31 – 35 15 5(33.3%) 5(33.3%) 4(26.7%) 
36 – 40 13 3(23.1%) 1(7.7%) 3(23.1%) 
Total 135 43  23  30  
 
TABLE-4 
Parity Distribution of the Patients in Relation to Outcome  
Parity Total No. of 
Patients  
Outcome (Maternal & Fetal) 
Congestive heart 
failure 
  
  
  
  
 p
-v
a
lu
e
 
 
Preterm 
delivery 
  
  
  
  
 p
-v
a
lu
e
 
 
Intrauterine growth 
restriction 
  
  
  
  
 p
-v
a
lu
e
 
 
Primigravida 39 12(30.8%) 
p
 =
 0
.1
7
2
 
 
7(17.9%) 
p
 =
 0
.4
3
2
 
 
8(20.5%) 
p
 =
 0
.2
8
8
 
 
Nullipara 13 4(30.8%) 3(23.1%) 1(7.7%) 
Primipara 58 15(25.9%) 11(18.9%) 12(20.7%) 
Para 2–4  25 12(48%) 2(8%) 9(36%) 
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TABLE-5 
Gestational Age Distribution of the Patients in Relation to Outcome  
Gestation (in 
weeks) 
Total No. of 
Patients  
Outcome (Maternal & Fetal) 
Congestive heart 
failure 
  
  
  
  
 p
-v
a
lu
e
 
 
Preterm delivery 
 
 
Intrauterine growth 
restriction 
  
  
  
  
  
p
-v
a
lu
e
 
 
< 37  23 1(4.4%) 
p
 =
 0
.2
5
5
 
 
23(100%) 
p
 <
 
0
.0
0
0
1
 1(4.4%) 
p
 =
 0
.5
3
4
 
 
37 and more 112 42(37.5%) 0(0%) 29(25.9%) 
Total 135 43  23  30  
 
DISCUSSION 
Heart diseases are the most important non obstetrical causes of maternal deaths during pregnancy. Pregnant 
patient with heart disease is a unique challenge to the obstetrician, dealing with high risk pregnancies and 
requires a thorough understanding of the impact of pregnancy on the haemodynamic response to the patient's 
cardiac lesion. The prevalence of pregnancy with rheumatic heart disease has decreased in developed countries 
in last two decades. Rheumatic heart disease is still the leading cause of death due to heart disease in young 
woman in the developing world. Women with valvular heart disease have an increased risk of adverse outcomes 
in pregnancy. Mitral stenosis is the most common, potentially lethal heart condition in pregnancy. Maternal risks 
are increased with severity of the lesion. Pregnant women with valvular heart disease have been reported 
significantly higher incidence of adverse fetomaternal outcome like congestive heart failure, preterm delivery, 
and IUGR. An increased incidence of congestive heart failure in patients with valvular heart disease is not 
surprising owing to the marked hemodynamic changes normally occurring during gestation. Perinatal outcome 
was also more adverse in the valvular heart disease as moderate and severe mitral stenosis have a clear effect on 
fetal outcomes. Present study was conducted to find fetomaternal outcome of pregnancy in case of mild–
moderate mitral stenosis. Age is an important factor because complications are associated with advanced age. 
Mean age of mothers was 29.09±4.43 years. Majority of the patients 88(65.2%) were between 26 to 30 years of 
age. Congestive heart failure was observed in 43 patients (31.9%), preterm deliveries in 23 (17.0%) and 
intrauterine growth restriction in 30(22.2%) cases. Almost similar results have been observed in national and 
international literature. Hameed et al,
23
 in a case-control study comparing women who had mitral stenosis with 
well matched controls found an increased incidence of preterm delivery (28% in moderate stenosis v 6% in 
controls, 44% in severe stenosis v 11% in controls) and intrauterine growth restriction (27% in moderate stenosis 
v 0% in controls, 33% severe stenosis v 0% in controls). Regarding maternal outcome, congestive heart failure in 
11% (2/19) cases as compared to 10% (0/19) controls in mild stenosis (p=0.5) while in moderate patients 
61%(11/18) cases versus 0%(0/18) controls had CHF (p=0.01). Ameen et al24 have reported that mild mitral 
lesion revealed congestive heart failure 0%(0/45), preterm deliveries 13.3%(6/45), in moderate mitral lesion 
congestive heart failure 37.5%(3/8), and preterm deliveries 12.5%(1/8) and in severe mitral lesion congestive 
heart failure 69.2%(9/13) and preterm deliveries 15.4%(2/13). 
 
Malhotra et al5 have evaluated maternal and fetal outcome in valvular heart disease and found congestive heart 
failure (5.1% vs. 0%, P<0.001) in cases and controls respectively. Perinatal outcome was also more adverse in 
the valvular heart disease group than in the control group, with increased preterm delivery rate (48.3% vs. 
20.5%) and reduced birth weight (2434±599 g vs. 2653±542 g; P<0.001). Tahira et alr
25
 assessed pregnancy 
outcome in cardiac disease. In their study 50 patients (67.6%) were in 20-25 years. Mitral stenosis was the most 
common lesion present in 40 patients (60.6%). Preterm delivery was 18.9% and there were 18% SGA babies. 
Stillbirth was in 2 patients (3%). Mazhar et al
12
 evaluated fetomaternal outcome in pregnancy with cardiac 
disease. In their study 28 (65.3%) had rheumatic heart disease and mitral valve disease was the commonest. The 
mean age was 27.50±5.17 years. Six infants (14.3%) had intrauterine growth restriction, 2 (4.8%) perinatal 
deaths occurred due to prematurity while there was 1 (2.4%) intrauterine death. Asghar et al
4
 evaluated outcome 
of pregnancy complicated by heart disease. Rheumatic heart disease was the common etiology (66%) and mitral 
valve was involved in all cases in their study. In 42% cases mitral stenosis was the isolated lesion. Congestive 
cardiac failure was observed in 10(21.2%) patients and preterm delivery in 7 patients (14%). 
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Wasim et al
26
 evaluated foetomaternal outcome of pregnancy with cardiac disease in five year study. Majority of 
patients were young age, 102 patients were less than 30 years of age out of 160 (63.75%). 55 were primigravida 
and 65% were diagnosed with cardiac lesions during pregnancy. Seventy five patients were para 2-4 and rest had 
more than 4 babies. Thirty six percent patients were diagnosed to have cardiac lesions for the first time during 
pregnancy. Acquired valvular heart defects were found in 132 (82%) patients with mitral stenosis being the 
commonest lesion (55%). Pre-maturity was found 20(14%), foetal death (IUGR + Foetal distress) 10(7%).  Ten 
cases (6.25%) of pregnant peripartum cardiomyopathy patients were seen. Six mothers (3.8%) expired in the 5 
year study period. 
 
S Sayeeda et al
27
 conducted a two years study on pregnant women with cardiac disease in a tertiary care centre at 
Bangladesh. The incidence of IUGR was 19.75% and 17.5% delivered at preterm. Akhter et al28 evaluated 
maternal and fetal outcome in valvular heart disease in pregnancy in a multicenter prospective study carried out 
over a period of 5 years at Bangladesh. The incidence of preterm birth and small for gestational age newborn 
was 11.69% and 13.36% respectively. There was one (1.67%) maternal death. They concluded that pregnancy in 
women with valvular heart disease is associated with remarkable unfavourable effect on maternal and fetal 
outcome which are related to severity of disease.  In one study Akhter et al
29
 found outcome of pregnancy in 
women with mitral stenosis. Preterm deliveries were 6(12%).Small for gestational age babies were 7(14%). 
Stillbirth was 1 (2%) and there were 4(8%) cases of atrial fibrillation. Lin et al
30
 revealed 18 of preterm labor 
medically (28%, 18/65), 4 of fetal growth restriction (6%, 4/65) in groups of NYHA class III and IV in their 
study. They concluded that pregnant women with rheumatic heart disease of moderate-severe mitral stenosis, 
severe pulmonary hypertension and atrial fibrillation are at high risk of heart failure. Yasmeen et al
31
 evaluated 
feto-maternal outcome in patients with cardiac disease in pregnancy. They found cardiac failure in 6 (15%) 
patients. Preterm labour was seen in 10 (25%) patients. 10 (25%) babies were growth restricted. 
 
CONCLUSION 
Among the complications, congestive heart failure had a high frequency of 31.9% followed by intrauterine 
growth restriction 22.2% and preterm deliveries 17.0%. Preterm delivery in patients with mitral stenosis was 
significantly high in age group 26–30 years.  
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